MX2015013525A - Metodo para tratar leucemia mieloide. - Google Patents

Metodo para tratar leucemia mieloide.

Info

Publication number
MX2015013525A
MX2015013525A MX2015013525A MX2015013525A MX2015013525A MX 2015013525 A MX2015013525 A MX 2015013525A MX 2015013525 A MX2015013525 A MX 2015013525A MX 2015013525 A MX2015013525 A MX 2015013525A MX 2015013525 A MX2015013525 A MX 2015013525A
Authority
MX
Mexico
Prior art keywords
myeloid leukemia
methods
treating myeloid
treating
effective amount
Prior art date
Application number
MX2015013525A
Other languages
English (en)
Other versions
MX363896B (es
Inventor
Amnon Peled
Yaron Pereg
Original Assignee
Biokine Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokine Therapeutics Ltd filed Critical Biokine Therapeutics Ltd
Publication of MX2015013525A publication Critical patent/MX2015013525A/es
Publication of MX363896B publication Critical patent/MX363896B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un método para tratar una leucemia mieloide. El método incluye la etapa de administrar a un sujeto en necesidad del mismo una cantidad terapéuticamente efectiva de un péptido antagonístico de CXCR4 y una cantidad terapéuticamente efectiva de un agente quimioterapéutico.
MX2015013525A 2013-03-24 2014-03-19 Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide. MX363896B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804677P 2013-03-24 2013-03-24
PCT/IL2014/050303 WO2014155376A1 (en) 2013-03-24 2014-03-19 Methods of treating myeloid leukemia

Publications (2)

Publication Number Publication Date
MX2015013525A true MX2015013525A (es) 2016-07-18
MX363896B MX363896B (es) 2019-04-05

Family

ID=50483415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013525A MX363896B (es) 2013-03-24 2014-03-19 Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide.

Country Status (13)

Country Link
US (3) US20160082071A1 (es)
EP (1) EP2978439B1 (es)
JP (1) JP6294459B2 (es)
KR (1) KR20150135432A (es)
CN (1) CN105163749B (es)
AU (2) AU2014240733B2 (es)
BR (1) BR112015024558A2 (es)
CA (1) CA2906314A1 (es)
ES (1) ES2643321T3 (es)
HK (1) HK1215790A1 (es)
IL (1) IL240924B (es)
MX (1) MX363896B (es)
WO (1) WO2014155376A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101719339B1 (ko) 2009-06-14 2017-03-23 바이오카인 테라퓨틱스 리미티드 혈소판 수준을 증가시키는 펩타이드 요법
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
JP6505681B2 (ja) * 2013-10-31 2019-04-24 バイオカイン セラピューティックス リミテッド Ｆｌｔ３変異を有する急性骨髄性白血病を治療するための医薬組成物
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
AU2017222495B2 (en) * 2016-02-23 2019-08-08 Biolinerx Ltd. Methods of treating acute myeloid leukemia
US20190233524A1 (en) * 2017-09-18 2019-08-01 Tcm Biotech International Corp. Therapeutic combination and method for treating cancer
CN113150068B (zh) * 2017-09-20 2023-04-04 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
EP3856225A1 (en) 2018-09-25 2021-08-04 BioLineRx Ltd. Methods of selecting treatment for cxcr4-associated cancer
EP3874042A4 (en) * 2018-10-29 2023-06-28 Molecular Stethoscope, Inc. Characterization of bone marrow using cell-free messenger-rna
CN110935008B (zh) * 2019-12-10 2023-09-26 昆明医科大学第一附属医院 一种关节腔注射治疗骨关节炎的tn14003温敏型凝胶及其制备方法
JP7441049B2 (ja) 2020-01-15 2024-02-29 カヤバ株式会社 ギヤの製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39282A (en) * 1863-07-21 Improvement in ch aim-shot
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS552602A (en) * 1978-06-20 1980-01-10 Yamasa Shoyu Co Ltd 1-beta-d-arabinofranosylcytosine-5'-phosphoric acid oleyl ester
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
DE60136373D1 (de) 2000-09-05 2008-12-11 Biokine Therapeutics Ltd Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten
JP4781621B2 (ja) * 2002-08-27 2011-09-28 バイオカイン セラピューティックス リミテッド Ｃｘｃｒ４拮抗薬およびその用途
US7423007B2 (en) * 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
CA2520406A1 (en) 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
US20070043012A1 (en) 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy

Also Published As

Publication number Publication date
JP6294459B2 (ja) 2018-03-14
KR20150135432A (ko) 2015-12-02
JP2016516080A (ja) 2016-06-02
ES2643321T3 (es) 2017-11-22
US20180344801A1 (en) 2018-12-06
CA2906314A1 (en) 2014-10-02
AU2014240733A1 (en) 2015-10-22
AU2014240733B2 (en) 2018-11-22
EP2978439A1 (en) 2016-02-03
HK1215790A1 (zh) 2016-09-15
US20160082071A1 (en) 2016-03-24
CN105163749A (zh) 2015-12-16
AU2019200329A1 (en) 2019-02-07
CN105163749B (zh) 2018-03-27
WO2014155376A1 (en) 2014-10-02
EP2978439B1 (en) 2017-08-16
MX363896B (es) 2019-04-05
US20180311308A1 (en) 2018-11-01
IL240924A0 (en) 2015-10-29
IL240924B (en) 2018-01-31
BR112015024558A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
MX2015013525A (es) Metodo para tratar leucemia mieloide.
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
PH12015502075B1 (en) Treatment of cataplexy
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
MX2015012106A (es) Combinacion de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cancer pulmonar de celulas no pequeñas.
MX2017015896A (es) Agente anticancerigeno.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
EP2968345A4 (en) DOUBLE MEK / PI3K INHIBITORS AND THERAPEUTIC PROCESSES USING SAME
TW201613592A (en) Glucose metabolism ameliorating agent
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2015011386A (es) Metodo para tratar cancer pancreatico.
EP3019138A4 (en) Guiding means for administering acupuncture and other healing procedures
MX2016002307A (es) Tratamiento para el cancer.
MX2015012344A (es) 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin.
GEP20196947B (en) Bremelanotide therapy for female sexual dysfunction
EP2981324A4 (en) METHODS AND ARTICLES MANUFACTURED FOR THE TREATMENT OF SKIN
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
UA88266U (ru) Способ комплексной профилактики и лечения поражений слизистой оболочки полости рта на фоне химиотерапии
CA149964S (en) Scarf
UA86152U (ru) Способ лечения больных хроническим гепатитом с, которые имеют противопоказания к интерферонотерапии, и/или нон-респондеров
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders

Legal Events

Date Code Title Description
FG Grant or registration